Pinpoint secures new investment to develop "ground-breaking" products
The financial backing will help the company to develop a new generation of microbial air monitors that enables continuous monitoring as demanded by the Annex 1 revision.
Pinpoint Scientific, specialist product designers and manufacturers of environmental monitoring solutions for the pharmaceutical and related industries, has secured further investment into the business, to aid the development of its ImpactAir range of environmental monitoring solutions.
Cherwell Laboratories and Development Bank of Wales (DBW) have both invested in Pinpoint and taken a minority share in the business. The investment not only secures jobs in South Wales, a key objective of DBW, but also allows the business to bring to the market some exciting new products within the ImpactAir range. Cherwell is an existing distributor of ImpactAir products within the UK and Andy Whittard, Cherwell’s Managing Director, has also taken a seat on the Pinpoint board to help with business strategy and planning.
Gethin Jones, Managing Director of Pinpoint and the designer of the ImpactAir product said: “This is an exciting time for Pinpoint. We have been working on very innovative ideas to develop a new generation of microbial air monitors to meet the new pharmaceutical regulations. This investment is perfect timing for Pinpoint and allows us to create a range of ground-breaking products for this market.”
Andy Whittard added: “I am really excited to join up with Gethin and the team at Pinpoint to help create an exciting range of products for pharma EM. The Annex 1 revision is potentially going to shift the dynamics for EM within grade A spaces and I think Pinpoint is well placed to service that need with innovative and highly effective monitoring devices.”
Sarah Smith, Investment Executive with the Technology Venture Investment team at the DBM said: “Our Wales Technology Seed Fund provides businesses like Pinpoint with the funding that they need to further develop their products. Together with Cherwell Laboratories, we will work with the team to support their growth in this niche sector as providers of continuous air quality for life science cleanrooms. This is an exciting time for the team as they look to capitalise on their existing customer base and scale the business. We wish them every success.”
The ImpactAir range of microbial air samplers is shortly to be expanded with the introduction of the new ImpactAir ISO-90 Monitoring Platform. ImpactAir is designed for continuous monitoring in high-grade areas, where in-process sampling of viable particles is often critical. The ImpactAir ISO is a modular system designed to integrate into isolators or RABS, using an external controller and local or remotely located air mover. It can be designed in almost any orientation using standard or custom-made connections. The ISO-90-Monitoring Head features a chamber for 90-mm agar plates and a highly efficient slit to agar sampling method. The low D50 value and ability to sample for long periods makes the ISO-90 ideal for continuous monitoring as demanded by the Annex 1 revision.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance